Copyright
©The Author(s) 2024.
World J Exp Med. Sep 20, 2024; 14(3): 95540
Published online Sep 20, 2024. doi: 10.5493/wjem.v14.i3.95540
Published online Sep 20, 2024. doi: 10.5493/wjem.v14.i3.95540
Table 1 Clinical characteristics of the study population
| Characteristics | Number |
| Age in yr | 64.5 (53-72) |
| Sex | |
| Male | 249 (59.6) |
| Female | 169 (40.4) |
| Risk factor | |
| Hypertension | 299 (71.5) |
| Dyslipidemia | 276 (66) |
| Diabetes mellitus | 141 (33.7) |
| Atrial fibrillation/atrial flutter | 102 (24.4) |
| Old stroke | 47 (11.2) |
| Current smoking | 73 (17.5) |
| Current alcohol drinking | 42 (10) |
| Etiology | |
| Other determined or undetermined | 177 (42.3) |
| Cardioembolic | 102 (24.4) |
| Small-artery occlusion | 94 (22.5) |
| Large-artery atherosclerosis | 42 (10) |
| Medication before stroke onset | |
| Antihypertensive therapy | 202 (48.3) |
| Antiplatelet therapy | 81 (18.3) |
| Hypoglycemic therapy | 121 (27.3) |
| Time for stroke onset to intravenous rtPA infusion in min | 170.05 (124-218.25) |
| Infarct volume in mL | 3.27 (0.58-24.24) |
| Hemorrhagic transformation | |
| No | 343 (82) |
| Yes | 75 (82) |
| PH1 | 29 (82) |
| PH2 | 27 (6.1) |
| HI1 | 12 (2.7) |
| HI2 | 7 (1.6) |
Table 2 Clinical characteristics of the study population (continued)
| Characteristics | Number |
| Baseline blood glucose in mg% | 110 (96-141) |
| Laboratory tests | |
| Hb | 13.3 (12.2-14.4) |
| WBC as 109/L | 8.4 (6.81-10.51) |
| Platelets as 109/L | 227 (192-278) |
| Neutrophil as 109/L | 5.14 (3.8-7.06) |
| Lymphocyte as 109/L | 1.93 (1.36-2.7) |
| P/NR | 43.73 (32.0-59.04) |
| PLR | 115.33 (87.17-170.64) |
| NLR | 2.56 (1.61-4.52) |
| PWR | 27.07 (21.4-33.99) |
| LDL | 114.5 (89-143) |
| NIHSS on admission | 10 (6-16) |
| NIHSS score on discharge date (day 1-7) | 5 (1-10) |
| Outcome events | |
| Increase NIHSS from baseline or death within 7 d after IV rt-PA | |
| Poor outcome (≥ 4 score) | 24 (5.7) |
| Good outcome (< 4 score) | 394 (94.3) |
| mRS on admission | 5 (3.75-5) |
| Poor outcome (3-6) | 348 (83.3) |
| Good outcome (0-2) | 70 (16.7) |
| mRS on discharge date (day 1-7) | 3 (1-4) |
| Poor outcome (3-6) | 236 (56.5) |
| Good outcome (0-2) | 182 (43.5) |
| mRS at 3 mo | 2 (0-4) |
| Poor outcome (3-6) | 168 (40.2) |
| Good outcome (0-2) | 250 (59.8) |
Table 3 Clinical characteristics of patients according to presence/absence of early neurological deterioration and hemorrhagic transformation after intravenous recombinant tissue plasminogen activator treatment
| Variables | Total, n = 418 | No E-ND, n = 394 | E-ND, n = 24 | P value | No HT, n = 342 | HT, n = 75 | P value |
| Age in yr | 64.5 (53-72) | 64 (52-71) | 70 (58.75-77.25) | 0.0451 | 65 (53-72) | 64 (52-74) | 0.9391 |
| Sex | |||||||
| Male | 249 (59.6) | 237 (60.2) | 12 (50) | 0.3252 | 206 (60.2) | 42 (56.0) | 0.4992 |
| Female | 169 (40.4) | 157 (39.8) | 12 (50) | 136 (39.8) | 33 (44.0) | ||
| Risk factor | |||||||
| Hypertension | 299 (71.5) | 279 (71.2) | 20 (83.3) | 0.1982 | 245 (72.1) | 53 (70.7) | 0.8082 |
| Dyslipidemia | 276 (66.0) | 261 (66.9) | 15 (62.5) | 0.6552 | 223 (65.8) | 52 (70.3) | 0.4582 |
| Diabetes mellitus | 141 (33.7) | 126 (32.1) | 15 (62.5) | 0.0022 | 114 (33.4) | 26 (34.7) | 0.8382 |
| Atrial fibrillation/ atrial flutter | 102 (24.4) | 97 (24.6) | 5 (20.8) | 0.6752 | 81 (23.7) | 21 (28.0) | 0.4312 |
| Old stroke | 47 (11.2) | 44 (11.3) | 3 (12.5) | 0.8522 | 44 (13.0) | 3 (4.0) | 0.0272 |
| Current smoking | 73 (17.5) | 70 (82.4) | 3 (100) | 0.4242 | 62 (83.8) | 10 (76.9) | 0.5462 |
| Current alcohol drinking | 42 (10.0) | 42 (91.3) | 0 (0) | 0.0032 | 37 (90.2) | 5 (83.3) | 0.6082 |
| Etiology | |||||||
| Other determined or undetermined | 177 (42.3) | 161 (41.2) | 16 (66.7) | 0.0052 | 143 (42.1) | 34 (45.3) | < 0.0012 |
| Cardioembolic | 102 (24.4) | 100 (25.6) | 2 (8.3) | 73 (21.5) | 29 (38.7) | ||
| Small-artery occlusion | 94 (22.5) | 93 (23.8) | 1 (4.2) | 91 (26.8) | 3 (4.0) | ||
| Large-artery atherosclerosis | 42 (10) | 37 (9.5) | 5 (20.8) | 33 (9.7) | 9 (12.0) | ||
| Medication | |||||||
| Antihypertensive therapy | 202 (45.6) | 75 (19.0) | 6 (25.0) | 0.4732 | 165 (48.2) | 37 (49.3) | 0.8642 |
| Antiplatelet therapy | 81 (18.3) | 191 (48.5) | 11 (45.8) | 0.8012 | 63 (18.4) | 18 (24.0) | 0.2692 |
| Hypoglycemic therapy | 121 (27.3) | 111 (28.2) | 10 (41.7) | 0.162 | 96 (28.2) | 25 (33.3) | 0.3712 |
| Infarct volume in mL | 3.27 (0.58-24.24) | 2.76 (0.45-20.25) | 34.42 (5.57-303.93) | < 0.0011 | 2.67 (0.43-16.88) | 13.99 (1.11-73.07) | 0.3891 |
| Time for stroke onset to intravenous rtPA infusion in min | 170.05 (124-218.25) | 170 (122-217) | 180.5 (147.5-232.25) | 0.1571 | 172 (124.85-218.25) | 160 (124-219) | 0.5161 |
Table 4 Clinical characteristics of patients according to presence/absence of delayed neurological deterioration and 3-mo outcome after intravenous recombinant tissue plasminogen activator treatment
| Variables | Total, n = 418 | No D-ND, n = 182 | D-ND, n = 236 | P value | Good 3-months, n = 250 | Poor 3-months, n = 168 | P value |
| Age in yr | 64.5 (53-72) | 60 (49-67.25) | 67 (58-76.75) | < 0.0011 | 60 (50-68) | 69 (61-75) | < 0.0011 |
| Sex | |||||||
| Male | 249 (59.6) | 120 (65.9) | 129 (54.7) | 0.022 | 162 (64.8) | 87 (51.8) | 0.0082 |
| Female | 169 (40.4) | 62 (34.1) | 107 (45.3) | 88 (35.2) | 81 (48.2) | ||
| Risk factor | |||||||
| Hypertension | 299 (71.5) | 114 (62.6) | 185 (79.1) | < 0.0012 | 163 (65.2) | 136 (81.9) | < 0.0012 |
| Dyslipidemia | 276 (66.0) | 113 (62.8) | 163 (69.7) | 0.1412 | 162 (65.3) | 114 (68.7) | 0.4782 |
| Diabetes Mellitus | 141 (33.7) | 55 (30.4) | 86 (36.4) | 0.1952 | 73 (29.3) | 68 (40.5) | 0.0182 |
| Atrial fibrillation/atrial flutter | 102 (24.4) | 40 (22.0) | 62 (26.3) | 0.3112 | 53 (21.2) | 49 (29.2) | 0.0632 |
| Old stroke | 47 (11.2) | 16 (8.8) | 31 (13.2) | 0.162 | 24 (9.7) | 23 (13.7) | 0.212 |
| Current smoking | 73 (17.5) | 38 (86.4) | 35 (79.5) | 0.3952 | 52 (85.2) | 21 (77.8) | 0.392 |
| Current alcohol drinking | 42 (10.0) | 20 (95.2) | 22 (84.6) | 0.242 | 30 (88.2) | 12 (92.3) | 0.6852 |
| Etiology | |||||||
| Other determined or undetermined | 177 (42.3) | 69 (38.3) | 108 (46.0) | 0.0042 | 93 (37.5) | 84 (50.3) | 0.0022 |
| Cardioembolic | 102 (24.4) | 51 (28.3) | 51 (21.7) | 70 (28.2) | 32 (19.2) | ||
| Small-artery occlusion | 94 (22.5) | 50 (27.8) | 44 (18.7) | 66 (26.6) | 28 (16.8) | ||
| Large-artery atherosclerosis | 42(10) | 10 (5.6) | 32 (13.6) | 19 (7.7) | 23 (13.8) | ||
| Medication | |||||||
| Antihypertensive therapy | 202 (45.6) | 81 (44.5) | 121 (51.3) | 0.172 | 111 (44.4) | 91 (54.2) | 0.052 |
| Antiplatelet therapy | 81 (18.3) | 31 (17.0) | 50 (21.2) | 0.2872 | 44 (17.6) | 37 (22.0) | 0.2622 |
| Hypoglycemic therapy | 121 (27.3) | 53 (29.1) | 68 (28.9) | 0.9672 | 71 (28.5) | 50 (29.8) | 0.7832 |
| Infarct volume in mL | 3.27 (0.58-24.24) | 1.16 (0.05-7.88) | 7.61 (1.53-63.41) | 0.361 | 1.46 (0.13-7.93) | 16.62 (2.51-103.09) | 0.0131 |
| Time for stroke onset to intravenous rtPA infusion in min | 170.05 (124-218.25) | 182 (0-125) | 167.5 (120-219.5) | 0.5281 | 173.5 (125-218) | 166.5 (120-220) | 0.3061 |
- Citation: Chaiwisitkun A, Muengtaweepongsa S. Platelet-to-neutrophil ratio predicts hemorrhagic transformation and unfavorable outcomes in acute ischemic stroke with intravenous thrombolysis. World J Exp Med 2024; 14(3): 95540
- URL: https://www.wjgnet.com/2220-315x/full/v14/i3/95540.htm
- DOI: https://dx.doi.org/10.5493/wjem.v14.i3.95540